PT3952858T - Método de tratamento de tumores - Google Patents

Método de tratamento de tumores

Info

Publication number
PT3952858T
PT3952858T PT207871435T PT20787143T PT3952858T PT 3952858 T PT3952858 T PT 3952858T PT 207871435 T PT207871435 T PT 207871435T PT 20787143 T PT20787143 T PT 20787143T PT 3952858 T PT3952858 T PT 3952858T
Authority
PT
Portugal
Prior art keywords
treatment method
tumor treatment
tumor
treatment
Prior art date
Application number
PT207871435T
Other languages
English (en)
Portuguese (pt)
Original Assignee
QBiotics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019901280A external-priority patent/AU2019901280A0/en
Application filed by QBiotics Pty Ltd filed Critical QBiotics Pty Ltd
Publication of PT3952858T publication Critical patent/PT3952858T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT207871435T 2019-04-12 2020-04-09 Método de tratamento de tumores PT3952858T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2019901280A AU2019901280A0 (en) 2019-04-12 Method of Treatment

Publications (1)

Publication Number Publication Date
PT3952858T true PT3952858T (pt) 2026-02-26

Family

ID=72752169

Family Applications (1)

Application Number Title Priority Date Filing Date
PT207871435T PT3952858T (pt) 2019-04-12 2020-04-09 Método de tratamento de tumores

Country Status (26)

Country Link
US (1) US12226391B2 (cg-RX-API-DMAC7.html)
EP (1) EP3952858B1 (cg-RX-API-DMAC7.html)
JP (2) JP7900152B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210152531A (cg-RX-API-DMAC7.html)
CN (1) CN113924091A (cg-RX-API-DMAC7.html)
AU (1) AU2020256847B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020253A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136216C (cg-RX-API-DMAC7.html)
DK (1) DK3952858T3 (cg-RX-API-DMAC7.html)
EA (1) EA202192757A1 (cg-RX-API-DMAC7.html)
ES (1) ES3063750T3 (cg-RX-API-DMAC7.html)
FI (1) FI3952858T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260232T1 (cg-RX-API-DMAC7.html)
IL (1) IL287210B2 (cg-RX-API-DMAC7.html)
LT (1) LT3952858T (cg-RX-API-DMAC7.html)
MX (1) MX2021012449A (cg-RX-API-DMAC7.html)
MY (1) MY208979A (cg-RX-API-DMAC7.html)
PL (1) PL3952858T3 (cg-RX-API-DMAC7.html)
PT (1) PT3952858T (cg-RX-API-DMAC7.html)
RS (1) RS67777B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202110599RA (cg-RX-API-DMAC7.html)
SI (1) SI3952858T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202600066T1 (cg-RX-API-DMAC7.html)
UA (1) UA129840C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020206504A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202108677B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1971588T3 (da) * 2005-12-23 2012-10-22 Qbiotics Ltd Tiglien-3-onderivater
JP7013753B2 (ja) * 2017-09-15 2022-02-01 株式会社三洋物産 遊技機
BR112021024716A2 (pt) 2019-06-19 2022-02-08 QBiotics Pty Ltd Ruptura de biofilme
CN118451065A (zh) * 2021-12-21 2024-08-06 Q生物股份有限公司 结晶中间体
EP4638430A4 (en) * 2022-12-21 2026-07-01 QBiotics Pty Ltd CRYSTALLINE FORMS AND THEIR PRODUCTION PROCESSES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1971588T3 (da) * 2005-12-23 2012-10-22 Qbiotics Ltd Tiglien-3-onderivater
PT2986615T (pt) 2013-04-18 2019-03-22 Qbiotics Ltd Métodos e composições para a cicatrização de feridas
EP3490547A4 (en) * 2016-07-28 2020-04-01 QBiotics Pty Ltd TREATMENT METHOD
SG11201907891XA (en) * 2017-03-23 2019-09-27 QBiotics Pty Ltd Combination therapy for the treatment or prevention of tumours

Also Published As

Publication number Publication date
ZA202108677B (en) 2026-03-25
CA3136216A1 (en) 2020-10-15
SI3952858T1 (sl) 2026-04-30
WO2020206504A1 (en) 2020-10-15
AU2020256847A1 (en) 2021-11-11
IL287210B1 (en) 2025-03-01
UA129840C2 (uk) 2025-08-20
IL287210A (en) 2021-12-01
EA202192757A1 (ru) 2022-02-11
CN113924091A (zh) 2022-01-11
MY208979A (en) 2025-06-14
ES3063750T3 (en) 2026-04-20
FI3952858T3 (fi) 2026-02-18
US12226391B2 (en) 2025-02-18
RS67777B1 (sr) 2026-03-31
HRP20260232T1 (hr) 2026-03-27
SMT202600066T1 (it) 2026-03-09
LT3952858T (lt) 2026-04-10
US20220193023A1 (en) 2022-06-23
EP3952858A4 (en) 2022-05-25
SG11202110599RA (en) 2021-10-28
KR20210152531A (ko) 2021-12-15
EP3952858A1 (en) 2022-02-16
CA3136216C (en) 2024-01-16
AU2020256847B2 (en) 2025-05-15
MX2021012449A (es) 2021-11-12
IL287210B2 (en) 2025-07-01
EP3952858B1 (en) 2025-12-17
JP7900152B2 (ja) 2026-08-04
BR112021020253A2 (pt) 2021-12-07
JP2022528915A (ja) 2022-06-16
DK3952858T3 (da) 2026-02-23
PL3952858T3 (pl) 2026-03-30
JP2025060945A (ja) 2025-04-10

Similar Documents

Publication Publication Date Title
IL269026A (en) Methods of treating tumor
IL282794A (en) Therapeutic methods
IL283838A (en) Method of treating cancer with a cancer therapy in combination with another therapeutic agent
IL285771A (en) Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
IL285847A (en) Methods for treating map3k8 positive cancers
IL272081A (en) Photodynamic therapy method for skin disorders
EP3757187A4 (en) SURFACE TREATMENT AGENT
PL3288581T3 (pl) Sposób leczenia nowotworu
HUE053191T2 (hu) 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére
LT4034122T (lt) Hiperfenilalaninemijos gydymo būdai
IL291170A (en) Treatment of hr deficient cancer
PT3265087T (pt) Método de tratamento com tradipitant
IL281600A (en) Methods of treating cancer
IL308399A (en) Methods of treating cancer
IL281845A (en) Combination therapy for the treatment of cancer
SI3576740T1 (sl) Zdravljenje raka
PL3952858T3 (pl) Sposób leczenia guzów
EP3576791A4 (en) CALRETICULIN-MEDIATION CANCER TREATMENT
IL256000A (en) Quantifying her 2 protein for optimal cancer therapy
IL272379A (en) Methods of treating cancer by inhibiting setd2
IL270867A (en) Treatment method
IL281839A (en) Treatment methods
IL281792A (en) Treatment methods
EP4025203A4 (en) CANCER TREATMENT
IL280968A (en) Combination therapy